Rare Disease Advisor’s Post

Thank you for sharing this intriguing case study from Cureus Journal of Medical Science! Highlighting rare and complex cases such as this one is essential for advancing our understanding and improving patient care. This case underlines the importance of thorough clinical evaluation and the need for continued research in autoimmune liver diseases. Read the full article on Cureus here: https://lnkd.in/eStF6jzd

Sone good news in this study. While diabetes is becoming the leading cause of liver disease and there are few medical treatments available to slow the progression to cirrhosis. NEJM Group published phase 2b ENLIVEN trial evaluating FGF21 analog pegozafermin showing significant improvements and even reduction in fibrosis. Looking forward to seeing further studies for the millions with diabetes and obesity at risk for liver disease. #diabetes #liverdisease American Diabetes Association #obesity #t2d https://lnkd.in/eam35rFn

Severe cases of COVID-19 can lead to serious complications, including patients needing supplemental oxygen due to respiratory issues such as pneumonia and acute respiratory distress syndrome (ARDS). In a recent study, Mayo Clinic researchers evaluated the use of a class of anti-inflammatory drugs known as corticosteroids in these cases. The study assessed biomarker-concordant corticosteroid use in patients tested for a protein that causes inflammation. Learn more. https://mayocl.in/3Yn3Dmj

Extra intestinal manifestations are common in IBD patients. Hepatobilliary manifestations are among the most common and burdensome of the extra intestinal manifestations. In our latest meta analysis of 1.7 million IBD patients, we assessed the prevalence of different hepatic manifestations. You can access our article in the following link: https://lnkd.in/dP5uiusv Massoud Vosough, MD, Ph.D Bahareh Sadri Mohammad Amin Shahrbaf Mohammad Ali Mansournia

🧐Check out #Review: New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis 🎓 by Dr. Grigorescu Elena-Daniela. Dr. Cristina Lacatusu et al., from Grigore T. Popa University of Medicine and Pharmacy Iași 📄Enjoy reading: https://lnkd.in/e23W2ctN #non-alcoholic fatty liver disease; #coronary artery disease; #cardiovascular risk; #liver-heart axis

https://lnkd.in/g8GxaHUN Liver Disease Important Question And Answers Question.1. Write short note on tender hepatomegaly. Question.2. Enumerate causes of tender hepatomegaly. Question.3. Write short note on ascites. Question.4. Enumerate causes of ascites. Question.5. Describe causes, clinical features, diagnosis and management of jaundice #hepatomegaly #ascites #jaundice #generalmedicine

We are thrilled to share our recent findings on the use of plasma cathepsin D as a diagnostic indicator for alcohol-related liver disease (ALD). While advanced stages of ALD are relatively easy to detect, early detection remains a significant challenge. Our study has shown that plasma levels of the lysosomal enzyme cathepsin D are particularly associated with the early stages of ALD and exhibit promising diagnostic performance. This breakthrough could pave the way for more effective early diagnosis and intervention, potentially transforming the management of ALD. You can read the full paper here: https://lnkd.in/eA3uHvbu. #MedicalResearch #LiverDisease #EarlyDetection #ALD #CathepsinD #ScientificBreakthrough

This JAMA Clinical Guidelines Synopsis summarizes the American Association of Clinical Endocrinology’s 2022 clinical practice guideline for diagnosis and management of nonalcoholic fatty liver disease. cc: #UEGWeek2023 #UEGWeek https://ja.ma/46S2iHj

This week, we published a series of articles aimed at supporting healthcare professionals managing medicines 💊 in individuals with liver disorders. Our first article outlines how to assess liver function and interpret liver function tests ⬇ https://lnkd.in/ewztD6cJ Our second article outlines how to gather helpful background on the history of liver impairment and type of liver disease. This information is essential to support risk assessment ⚖ and decisions about treatment ⬇ https://lnkd.in/ecxmK35T Our third article in the series provides information about the resources 📚 available to support healthcare professionals in advising on medicines use in liver impairment ⬇ https://lnkd.in/ezVzJFkV

Exciting news in the world of liver research! UC San Diego NAFLD Research Center has been awarded a $9.57 million grant to conduct a clinical trial on a potential treatment for nonalcoholic fatty liver disease (NAFLD). This silent and potentially deadly condition affects around 24% of US adults, leading to liver complications. This novel trial will screen participants using non-invasive methods applicable in primary care settings and could revolutionize the detection and care for patients with NAFLD. #LiverResearch #PatientCare #HealthCare https://lnkd.in/gcbi5mYd